vialroom

#retatrutide 2026-05-14

Thursday27 messages7 participantstimes are UTC
Highlights from this day
  • vik_verifies — is the GI worse than tirzepatide or about the same 11:24
  • tenpence — unrelated but research use only is on every vial and i treat it as exactly that, nobody here is prescribing 12:18
  • tenpence — Medutest came back 99.2 on one lot and 99 on the next from the same JEEP, both fine 13:58
  • is_this_forever — i went up too fast, got a fortnight of nothing but nausea, and dropped back two steps, for what its worth 16:47
VV

is the GI worse than tirzepatide or about the same

baseline  58
wk 2      61
wk 4      64
wk 6      67
wk 8      66
wk 10     65   (held dose from wk 7)

mine went up too

blood pressure stayed flat for me while heart rate moved, which i didnt expect

TE

anyone stayed at 10 for months rather than climbing

TE

unrelated but research use only is on every vial and i treat it as exactly that, nobody here is prescribing

baseline  58
wk 2      61
wk 4      64
wk 6      67
wk 8      66
wk 10     65   (held dose from wk 7)
OO

update on the earlier thing is TRIUMPH the phase 3 programme

[edited]
VV

phase 2 was still trending at the end which is why the phase 3 readout matters more than usual

is the glucagon arm what people mean by the energy expenditure thing

DP

stopped for 19 months and restarted at half my old dose, the ramp was easier second time, i could be wrong

PS

appetite suppression at 2 was stronger than my tirzepatide experience at a comparable point

TE

does the energy expenditure claim show up as anything you can feel

Medutest came back 99.2 on one lot and 99 on the next from the same JEEP, both fine

TE

quick one nobody should read my log as a plan, im recording what i did and thats all it is, happy to be corrected
GI was about the same as tirzepatide for me, the difference was how fast it arrived

IT

i went up too fast, got a fortnight of nothing but nausea, and dropped back two steps, for what its worth

Cited study
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
New England Journal of Medicine · 2023
48 weeks, dose-ranging. A Phase 2 result is not a safety record.

right so triple agonist, GLP-1 and GIP and glucagon. the glucagon arm is the part with no long history

TRIUMPH is phase 3

[edited]
Cited study
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
New England Journal of Medicine · 2023
48 weeks, dose-ranging. A Phase 2 result is not a safety record.

came off at 4 weeks because my resting rate stayed elevated and i didnt like it

there is no long term safety data, phase 2 and an ongoing phase 3 programme is what exists